Type:Tablet
Generic Name:Tenofovir Disoproxil Fumarate
Manufacturer:Popular Pharmaceuticals Ltd.
Price:৳85.00
HIV-1 infection, Chronic hepatitis B
May be taken with or without food. Take consistently either always w/ or always w/o food.
Oral Chronic hepatitis B; HIV infection (Indicated in combination with other antiretroviral agents for treatment of HIV-1 infection) Adult: 300 mg once daily.
HIV Infection <2 years: Safety and efficacy not established >2 years: 8 mg/kg PO qDay; not to exceed 300 mg/day Hepatitis B Infection <12 years: Safety and efficacy not established >12 years; <35 kg: Safety and efficacy not established >12 years; >35 kg: 300 mg PO qDay
Renal impairment: Haemodialysis patients: 300 mg once every 7 days or after a cumulative total of 12 hr of dialysis. CrCl (ml/min) Dosage Recommendation 10-29 300 mg 72-96 hrly. 30-49 300 mg 48 hrly.
Tenofovir is contraindicated in patients with previously demonstrated hypersensitivity to Tenofovir or any component of the product.
Tenofovir disoproxil fumarate, a diester prodrug of tenofovir, is a nucleotide reverse transcriptase inhibitor. After oral absorption, tenofovir disoproxil fumarate is rapidly converted to tenofovir and then undergo subsequent phosphorylation by cellular enzymes to the active tenofovir diphosphate, which inhibits the activity of HIV-1 reverse transcriptase.
Patient w/ hepatomegaly or other risk factors for liver disease. Renal impairment. Pregnancy. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal function and serum phosphate concentrations before start of therapy, 4 wkly during the 1st wk, and then 3 mthly; hepatic function for several mth following discontinuation. Determine HIV status in all hepatitis B virus (HBV) infected patients prior to treatment. Lactation: HIV+ women are advised not to breastfeed
>10% Asthenia (11%),Diarrhea (16%),Nausea (11%),Pain (12%) 1-10% Anorexia,Depression,Myalgia,Peripheral neuropathy,Dyspepsia,Rash,Headache,Vomiting,Flatulence,Abdominal pain,Neutropenia,Increased transaminases
Decreased atazanavir concentration with tenofovir unless also co-administered with ritonavir. Increased serum concentration of tenofovir or co-administered drug if taken with drugs that are eliminated by active tubular secretion. Potentially Fatal: Increased risk of renal impairment with recent or concurrent use of nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2); monitor renal function wkly if unavoidable. Increased didanosine levels and thereby increasing risk of pancreatitis and peripheral neuropathy, with a high treatment failure rate with concurrent use; avoid concurrent use.
